INCORPORATING HEALTH INEQUALITIES (HIS) CONSIDERATIONS INTO UNITED KINGDOM (UK) HTA DECISION MAKING AND THE IMPACT ON RARE DISEASE MEDICINES

被引：0

|

作者：

Patel, A. ^{[1
]}

Guest, S. ^{[2
]}

Holdgate, O. ^{[2
]}

Rouse, P. ^{[3
]}

Furby, H. ^{[3
]}

Bradley, S. ^{[2
]}

机构：

[1] Roche Prod Ltd, Welwyn Garden City, Herts, England

[2] Roche Prod Ltd, Welwyn Garden City, England

[3] Roche Prod Ltd, London, England

来源：

VALUE IN HEALTH | 2023年 / 26卷 / 12期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

HTA242

引用

收藏

页码：S366 / S366

页数：1

相关论文

共 4 条

[1] Use of health impact assessment in incorporating health considerations in decision making
Davenport, C
Mathers, J
Parry, J
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2006, 60 (03) : 196 - 201
[2] EQUITY AND HEALTH INEQUALITIES: SHOULD DCEA BE CONSIDERED FOR DECISION MAKING IN THE UNITED KINGDOM?
Rouse, P.
Wodenitscharow, K.
VALUE IN HEALTH, 2022, 25 (01) : S86 - S86
[3] Using urgent small bowel ultrasound (SBUS) as a tool for decision-making in patients with inflammatory bowel disease (IBD): retrospective analysis of United Kingdom (UK) patients' outcome
Lehmann, A.
Nandra, G.
Power, N.
Lindsay, J. O.
Lindsay, James Oliver
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 838 - 839
[4] A COMPARISON BETWEEN ICER (US) AND NICE (UK) HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISION-MAKING FOR PD-1 INHIBITORS IN NON-SMALL-CELL LUNG CARCINOMA (NSCLC): OTHER BENEFITS AND CONTEXTUAL CONSIDERATIONS.
Cork, D.
Curry, A.
Ralston, S.
Dawson, L.
VALUE IN HEALTH, 2019, 22 : S99 - S99